KhanhC.Hoang

KhanhC.Hoang Updated 

This stock has a nice and wide trading range since both buyers and sellers have their valid trading thesis.

KhanhC.Hoang

According to the CFRA, its "12-month target price of $72 reflects an EV/ EBITDA multiple of about 12.5x our 2022 estimate, a notable discount versus its hotels and lodging peers ... potential upside on the recent strategic realignment with the expected return of leisure travel spending, potentially by H2 2021. Meanwhile, in May 2020, TNL suspended its share...

KhanhC.Hoang

when a pet lover receives the government check, she/he will definitely get the best stuffs for her/his pet.

KhanhC.Hoang

Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology.

KhanhC.Hoang Updated 

back in Oct 2020 -> "an early Moderna (MRNA) investor and Harvard PhD, Timothy Springer, continued to pour his fortune into this small cap stock. Mr. Springer also happens to be a director at Selecta Biosciences. He reportedly purchased more than 6,500,000 shares in October. He went on a shopping spree on October 7 when he bought 654,953 shares at $1.65 and...

KhanhC.Hoang

one boss who has managed two different companies in two different sectors is doing soul-searching to find new market in Africa.

KhanhC.Hoang

Based on BoA's round of calls with key Salesforce SI partners to gauge activity during the quarter, "feedback suggests deal activity tracked slightly above expectations, with strength across the Salesforce platform. Core Marketing Cloud and Service Cloud maintained solid recent momentum. There is increased focus on the Marketing Cloud, given added automation...

KhanhC.Hoang Updated 

Notes from web browsing: "Assessing Qualcomm’s outsized gains, J.P. Morgan analyst believes “Qualcomm shares have reacted positively to the company successfully leveraging the 5G smartphone opportunity.” However, taking this into consideration, Chatterjee wonders how much upside is left from the 5G exposure. Luckily for Qualcomm, the company has other significant...

KhanhC.Hoang

... a team of 40+ employees and still hiring ... I'm keeping trading it as long as COVID-19 is still a political headline.

KhanhC.Hoang

If I want to enter this trade, I will setup a limit order to buy it at $0.8; stop-loss at $0.75

KhanhC.Hoang

It's currently a 21-team with a decent pipeline so everything in R&D will be outsourced. It's tough speed up a project when the company is not fully in-controlled.

KhanhC.Hoang

Hexo is still in the leading quadrant of the wkly #rrgchart (from Stockcharts.com)

KhanhC.Hoang Updated 

notes from BOA Global Research before its earning on 02/09: " FY21 has been a transition year as it resets its strategic focus, rolls out a new organizational design and implements operational and supply chains productivity prgms. We look for a progress update on its reset, COVID’s impact on its business, strong growth in the value segment, along with a review of...

KhanhC.Hoang

According to its website, it is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. Our expertise across R&D, manufacture, and discovery of novel gene and cell therapies has us uniquely positioned to bring new medicines to patients in need.

KhanhC.Hoang

trading earning is a gambling activity; risk management through options help minimize the loss.

KhanhC.Hoang

a promising antibiotics with a team of 28(?) employees ... take the money and run now or trade along with the positive volume flow?

KhanhC.Hoang

I don't like trading a company that relies heavily only on the Democrats. Before I joined Tradingview, I bought its common shares in September betting that my great #45 had no chance for another 4 years. I then sold my PLUG shares before Christmas.

KhanhC.Hoang Updated 

I have been trading NKTR in a tight range. It may be time to widen my trading range.